PepGen (PEPG) Assets Average (2022 - 2026)
PepGen (PEPG) posted Assets Average of $165.1 million for Q1 2026, down 9.28% sequentially from $182.0 million in Q4 2025, and up 18.66% YoY from $139.1 million in Q1 2025.
Analysis
PepGen (PEPG) Assets Average (2022 - 2026) Analysis & Trends
PepGen has reported Assets Average for 5 years, with the latest figure at $165.1 million in Q1 2026.
- Quarterly Assets Average rose 18.66% year-over-year to $165.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.1 million (up 18.66% YoY) and the FY2025 annual result came in at $162.4 million, up 10.5% from the prior year.
- Assets Average eased to $165.1 million in Q1 2026 per PEPG's latest filing, from $182.0 million in the prior quarter.
- Over five years, Assets Average peaked at $219.6 million in Q3 2022 and troughed at $114.8 million in Q2 2025.
- A 5-year average of $173.2 million and a median of $175.0 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average jumped 51.89% in 2023, then sank 42.66% in 2025.
- Over 5 years, Assets Average stood at $213.0 million in 2022, then slipped by 27.84% to $153.7 million in 2023, then advanced by 4.49% to $160.6 million in 2024, then climbed by 13.34% to $182.0 million in 2025, then slipped by 9.28% to $165.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $165.1 million, $182.0 million, and $146.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 148.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 148.85 Mn |
| Mar 31, 2026 | 165.10 Mn |
| Dec 31, 2025 | 181.98 Mn |
| Sep 30, 2025 | 146.15 Mn |
| Jun 30, 2025 | 114.82 Mn |
| Mar 31, 2025 | 139.14 Mn |
| Dec 31, 2024 | 160.56 Mn |
| Sep 30, 2024 | 181.87 Mn |
| Jun 30, 2024 | 200.26 Mn |
| Mar 31, 2024 | 175.03 Mn |
| Dec 31, 2023 | 153.66 Mn |
| Sep 30, 2023 | 173.18 Mn |
| Jun 30, 2023 | 191.56 Mn |
| Mar 31, 2023 | 209.24 Mn |
| Dec 31, 2022 | 212.95 Mn |
| Sep 30, 2022 | 219.63 Mn |
| Jun 30, 2022 | 181.34 Mn |
| Mar 31, 2022 | 137.76 Mn |